<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" orientation="portrait" position="float">
 <label>Table 2.
  <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml"> </span>
 </label>
 <caption>
  <title>Therapies in research and development as potential therapies for SARS-CoV-2 infection.</title>
 </caption>
 <!--OASIS TABLE HERE-->
 <table frame="hsides" rules="groups">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead valign="top">
   <tr>
    <th align="left">Therapies</th>
    <th align="left">Type</th>
    <th align="left">Pharmaceutical company</th>
    <th align="left">Website</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td align="left">TJM2</td>
    <td align="left">Neutralizing antibody</td>
    <td align="left">I-Mab Biopharma</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="http://www.i-mabbiopharma.com/en/article-491.aspx" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.i-mabbiopharma.com/en/article-491.aspx</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">AT-100</td>
    <td align="left">Human recombinant protein</td>
    <td align="left">Airway Therapeutics</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.airwaytherapeutics.com/at-100/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.airwaytherapeutics.com/at-100/</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">TZLS-501</td>
    <td align="left">Human monoclonal antibody (mAb)</td>
    <td align="left">Tiziana Life Sciences</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.tizianalifesciences.com/our-drugs/anti-il-6r/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.tizianalifesciences.com/our-drugs/anti-il-6r/</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">OYA1</td>
    <td align="left">Antiviral</td>
    <td align="left">OyaGeninc</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="http://www.oyageninc.com/wordpress/drugs" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.oyageninc.com/wordpress/drugs</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">NP-120</td>
    <td align="left">Antifibrotic</td>
    <td align="left">Algernon Pharmaceuticals</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://algernonpharmaceuticals.com/?s=NP-120" xmlns:xlink="http://www.w3.org/1999/xlink">https://algernonpharmaceuticals.com/?s=NP-120</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">APN01</td>
    <td align="left">Recombinant human angiotensin-converting enzyme 2 (rhACE2)</td>
    <td align="left">Apeiron Biologics</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.apeiron-biologics.com/project-overview/#APN01" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.apeiron-biologics.com/project-overview/#APN01</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">Brilacidin</td>
    <td align="left">Antibacterial, anti-inflammatory, and immune modulator</td>
    <td align="left">Innovation Pharmaceuticals</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="http://www.ipharminc.com/brilacidin-1?rq=Brilacidin" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ipharminc.com/brilacidin-1?rq=Brilacidin</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">Leronlimab</td>
    <td align="left">Monoclonal antibody</td>
    <td align="left">CytoDyn</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.cytodyn.com/our-science" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cytodyn.com/our-science</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">REGN3048 and REGN3051</td>
    <td align="left">Combination of neutralizing monoclonal antibodies</td>
    <td align="left">Regeneron</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.regeneron.com/search-regeneron?query=REGN3048" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.regeneron.com/search-regeneron?query=REGN3048</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">SNG001</td>
    <td align="left">Interferon-β</td>
    <td align="left">Synairgen Research</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.synairgen.com/covid-19/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.synairgen.com/covid-19/</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">Nanobody</td>
    <td align="left"> </td>
    <td align="left">Beroni Group</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">Galidesivi
     <bold>r</bold>
    </td>
    <td align="left">Antiviral</td>
    <td align="left">Biocryst</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.biocryst.com/our-program/galidesivir/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.biocryst.com/our-program/galidesivir/</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">CYNK-001</td>
    <td align="left">Natural killer (NK) cell therapy</td>
    <td align="left">Celularity and Sorrento Therapeutics</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.celularity.com/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.celularity.com/</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">Remestemcel-L</td>
    <td align="left">Allogeneic mesenchymal stem cell (MSC) product candidate</td>
    <td align="left">Mesoblast</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc" xmlns:xlink="http://www.w3.org/1999/xlink">http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">MAN-01</td>
    <td align="left">Antiglaucoma</td>
    <td align="left">Q Biomed and Mannin Research</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.sec.gov/Archives/edgar/data/1596062/000110465920027119/tm205231d1_10k.htm" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.sec.gov/Archives/edgar/data/1596062/000110465920027119/tm205231d1_10k.htm</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">Opaganib/RHB-107</td>
    <td align="left">Anticancer and anti-inflammatory/potential for use in multiple oncology gastrointestinal and indications</td>
    <td align="left">RedHill Biopharma</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&amp;LNGID=1&amp;TMID=178&amp;FID=2432&amp;PID=0&amp;IID=13253" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&amp;LNGID=1&amp;TMID=178&amp;FID=2432&amp;PID=0&amp;IID=13253</ext-link>
    </td>
   </tr>
   <tr>
    <td align="left">Antibody cocktail therapy</td>
    <td align="left">–</td>
    <td align="left">Regeneron Pharmaceuticals</td>
    <td align="left">
     <ext-link ext-link-type="uri" xlink:href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody" xmlns:xlink="http://www.w3.org/1999/xlink">https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody</ext-link>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
